← Research library

[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].

Observational study · 2020

What was studied
25 patients with schizotypal disorder
Main finding
A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.

Reported findings and study design

A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.

25 patients with schizotypal disorder; 14-day monotherapy phase with limited rescue phenazepam, followed by combination treatment if needed.

Dose, route and schedule

Dilept: 60, 120 or 200 mg/day for 14 days as monotherapy. Single 2 mg doses of phenazepam were permitted as rescue treatment; subsequent combination treatment must be distinguished from the monotherapy phase.

Protocol source ↗ · Indexed publication abstract

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Psychiatric and cognitive measuresReported favorable changes; no PANSS, CGI or WAIS-R deltas supplied
Participants25; mean age 33.4 ± 10.0 years
Studied doses60, 120 and 200 mg/day; strongest reported action at 200 mg/day

Small uncontrolled pilot with rescue and subsequent combination therapy; claims about superiority to other antipsychotics are not established by this design.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Small pilot with permitted or add-on phenazepam. The same 25 patients are described in the 2017 cognitive report. The 2021 active comparison may reuse the 15-person high-dose arm.

Related publications may describe some of the same participants or experiments.

Source details

Original full paper and 2017 dose-finding publication, with cohort comparison.

Full paper reviewed

Sources checked

Citation

Uncontrolled human reportFull text available

Neznamov GG, Bogdanova IO, Sunyakov TS, Dorofeeva OA, Kovalenok TV, Chepeluk AA. [The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Study source ↗ · DOI 10.17116/jnevro202012002122 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards